XORTX Therapeutics shares surge 22.84% premarket after securing 180-day extension to regain Nasdaq compliance.

XORTX Therapeutics surged 22.84% in premarket trading following a series of positive announcements, including an 180-day extension to regain compliance with Nasdaq’s minimum bid price requirement, a $1.1 million registered direct offering, and the acquisition of a renal anti-fibrotic therapeutic program from Vectus Biosystems. The company also advanced its gout treatment program with IND preparation for XORLO and highlighted ongoing genome-wide research in gout. These developments signaled progress in regulatory compliance, capital raising, and therapeutic pipeline expansion, likely boosting investor confidence.